| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CDT2; RAMP; DCAF2; L2DTL |
| WB Predicted band size | 79 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human DTL |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DTL抗体的3篇示例参考文献(内容为模拟，仅供参考)：
---
1. **文献名称**: *"A monoclonal antibody against DTL reveals its role in DNA replication licensing"*
**作者**: Tanaka S. et al.
**摘要**: 本研究开发了一种特异性识别DTL蛋白的单克隆抗体，证实DTL通过与Cdt1相互作用调控DNA复制许可，并在癌细胞中高表达，提示其与基因组不稳定性相关。
---
2. **文献名称**: *"DTL knockdown via antibody-mediated targeting inhibits tumor growth in vivo"*
**作者**: Chen L. et al.
**摘要**: 利用抗DTL抗体靶向降解DTL蛋白，显著抑制了异种移植肿瘤的生长，表明DTL可能作为癌症治疗的潜在靶点，尤其在过表达的实体瘤中效果显著。
---
3. **文献名称**: *"Immunohistochemical analysis of DTL expression in human tissues and its clinical implications"*
**作者**: Müller R. et al.
**摘要**: 通过免疫组化分析多组织样本，发现DTL在增殖活跃的细胞中高表达，并与乳腺癌、胶质瘤等恶性肿瘤的分级和预后不良相关，为诊断标志物研究提供依据。
---
**备注**：以上文献为示例，实际研究中请通过学术数据库(如PubMed、Web of Science)检索具体论文。若需真实文献，建议使用关键词“DTL antibody”、“denticleless E3 ligase”或结合研究领域进一步筛选。
**Background of DTL Antibodies**
DTL (DCAF2 or Denticleless) antibodies target the DTL protein, a substrate receptor component of the CRL4 (Cullin-RING ligase 4) ubiquitin ligase complex. DTL plays a critical role in cell cycle regulation, DNA replication, and repair by facilitating the ubiquitination and degradation of specific substrates, such as cell cycle inhibitors (e.g., p21. SET8) and replication-associated proteins. Its activity is particularly important during S-phase progression and the DNA damage response.
DTL is overexpressed in various cancers, including breast, lung, and colorectal malignancies, where it correlates with poor prognosis, likely due to its role in promoting genomic instability and uncontrolled proliferation. This makes DTL a potential therapeutic target. Antibodies against DTL are widely used in research to study its expression, localization, and interaction partners via techniques like Western blotting, immunofluorescence, and immunoprecipitation.
In therapeutic contexts, DTL antibodies are explored for their ability to disrupt CRL4-DTL function, thereby inhibiting tumor growth or sensitizing cancer cells to chemotherapy. Additionally, diagnostic applications leverage DTL antibodies to detect protein levels in clinical samples as a biomarker for cancer progression. Ongoing studies aim to refine antibody specificity and efficacy for both mechanistic research and translational oncology.
×
